Skip to content
Search

Latest Stories

Liberty House set to improve transparency

IN A bid to improve its transparency, Britain's largest steel firm Liberty House will publish its consolidated accounts and name a board of directors for the first time.
The latest move has come following a series of criticism that the Sanjeev Gupta-led business lacked transparency.
Liberty House and Gupta, 48, have been facing questions for not providing details about investors and how it funded its series of acquisitions.
The company's lack of financial transparency and corporate management have raised questions over the viability of the business empire.

The company has been in news for its disorderly series of business acquisitions. It reportedly took advantage of depressed asset prices.

Gupta’s company turns over £20 billion a year and has a staff strength of 35,000 across the globe.
Its 8,000-strong British workforce makes it the country’s largest steel firm.
The wealth controlled by Gupta has made him and his family the fifth largest landowner in Britain.
In 2019, having expanded into the US and Australia markets, Liberty House doubled in size with the acquisition of seven European steelworks of ArcelorMittal.
On consolidating his company’s accounts, Gupta told The Times he was on his way to having them published by February 2020 at the latest.
The latest move to ensure transparency will enable the business to refinance on the mainstream capital markets and lower its cost of capital.
About his use of non-conventional financing, he added: “We have bought (distressed) businesses that have not been able to access the debt markets in a typical way.”
On criticism of his unconventional lenders, Gupta said: “We have borrowed from willing and happy debt providers. Why is that an issue for anybody?”

More For You

pharmaceuticals

UK becomes the only country in the world to have secured a zero per cent tariff rate for pharmaceutical shipments

iStock

UK secures zero-tariff deal with US on pharmaceuticals

Highlights

  • UK pharmaceutical exports worth £5bn annually protected from US tariffs for three years.
  • NHS spending on medicines to double from 0.3 per cent to 0.6 per cent of GDP over next decade.
  • Deal safeguards jobs at major British drugmakers including GSK and AstraZeneca.
The UK has secured a landmark deal with the United States guaranteeing zero tariffs on pharmaceutical exports. The UK government said it was the only country in the world to have secured a zero per cent tariff rate for pharmaceutical shipments.

Under the agreement announced on Monday, the NHS will pay more for medicines in return for a three-year guarantee that US import taxes on pharmaceuticals made in Britain will remain at zero per cent.

The deal comes after US President Donald Trump threatened to raise tariffs to as high as 100 per cent on branded drug imports, raising alarm for major British drugmakers including GSK and AstraZeneca.

Keep ReadingShow less